Dynamic heterogeneity in COVID-19: Insights from a mathematical model.
Chrysovalantis VoutouriC Corey HardinVivek NaranbhaiMohammad R NikmaneshiMelin J KhandekarJustin F GainorLance L MunnRakesh K JainTriantafyllos StylianopoulosPublished in: PloS one (2024)
Critical illness, such as severe COVID-19, is heterogenous in presentation and treatment response. However, it remains possible that clinical course may be influenced by dynamic and/or random events such that similar patients subject to similar injuries may yet follow different trajectories. We deployed a mechanistic mathematical model of COVID-19 to determine the range of possible clinical courses after SARS-CoV-2 infection, which may follow from specific changes in viral properties, immune properties, treatment modality and random external factors such as initial viral load. We find that treatment efficacy and baseline patient or viral features are not the sole determinant of outcome. We found patients with enhanced innate or adaptive immune responses can experience poor viral control, resolution of infection or non-infectious inflammatory injury depending on treatment efficacy and initial viral load. Hypoxemia may result from poor viral control or ongoing inflammation despite effective viral control. Adaptive immune responses may be inhibited by very early effective therapy, resulting in viral load rebound after cessation of therapy. Our model suggests individual disease course may be influenced by the interaction between external and patient-intrinsic factors. These data have implications for the reproducibility of clinical trial cohorts and timing of optimal treatment.
Keyphrases
- sars cov
- immune response
- coronavirus disease
- clinical trial
- oxidative stress
- chronic kidney disease
- newly diagnosed
- end stage renal disease
- stem cells
- depressive symptoms
- bone marrow
- inflammatory response
- toll like receptor
- ejection fraction
- open label
- replacement therapy
- single cell
- single molecule
- smoking cessation
- data analysis